Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tifacogin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tifacogin | DRUG | - |
Inclusion Criteria: * Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence * Pneumonia of sufficient severity to require ICU admission and management Exclusion Criteria: * Pregnancy * Weight over 150 kg * Patients at increased risk...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | - | Undisclosed |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | - | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | N/A | Undisclosed |
Tifacogin is an investigational small molecule being studied for the treatment of severe community-acquired pneumonia. It is being developed by Novartis AG (NVS) and has completed a Phase 3 clinical trial. Tifacogin is not approved and remains in clinical development.
Tifacogin is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The drug is an investigational small molecule intended for the treatment of severe community-acquired pneumonia.
Tifacogin is in Phase 3 clinical development. A single Phase 3 trial has been completed, with no active trials currently ongoing. The drug is investigational and has not been approved for any use.
Tifacogin has been studied in one completed Phase 3 trial, NCT00084071, titled 'Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia.' The trial enrolled 2,136 participants across multiple countries, including the United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Malaysia, Netherlands, New Zealand, Peru, Singapore, South Africa, South Korea, Spain, and the United Kingdom.
No alternative names for Tifacogin have been disclosed. The drug is identified solely by its generic name, Tifacogin, in the available clinical trial information.